220 related articles for article (PubMed ID: 31856443)
1. [Clinical and prognostic values of TP53 mutation in patients with acute myeloid leukemia].
Zhang Y; Hu XX; Gao L; Ni X; Chen J; Chen L; Zhang WP; Yang JM; Wang JM
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):932-938. PubMed ID: 31856443
[No Abstract] [Full Text] [Related]
2. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
[TBL] [Abstract][Full Text] [Related]
3. [Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia].
Mi R; Guo Z; Liu W; Hu J; Fan R; Chen L; Liu J; Wei X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):955-960. PubMed ID: 34625931
[TBL] [Abstract][Full Text] [Related]
4. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
[No Abstract] [Full Text] [Related]
5. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
7. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
[TBL] [Abstract][Full Text] [Related]
9. [Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].
Huang HJ; Shi ZX; Li B; Qin TJ; Xu ZF; Zhang HL; Fang LW; Hu NB; Pan LJ; Qu SQ; Liu D; Cai YN; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):215-221. PubMed ID: 30929389
[No Abstract] [Full Text] [Related]
10. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K; Maiti A; Loghavi S; Pourebrahim R; Kadia TM; Rausch CR; Furudate K; Daver NG; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Tang G; Ravandi F; Kantarjian HM; DiNardo CD; Konopleva MY
Cancer; 2021 Oct; 127(20):3772-3781. PubMed ID: 34255353
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
Chen Y; Zheng J; Weng Y; Wu Z; Luo X; Qiu Y; Lin Y; Hu J; Wu Y
Ann Hematol; 2024 Apr; 103(4):1211-1220. PubMed ID: 38409598
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
14. Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
Terada K; Yamaguchi H; Ueki T; Usuki K; Kobayashi Y; Tajika K; Gomi S; Kurosawa S; Miyadera K; Tokura T; Omori I; Marumo A; Fujiwara Y; Yui S; Ryotokuji T; Osaki Y; Arai K; Kitano T; Kosaka F; Wakita S; Tamai H; Fukuda T; Inokuchi K
Ann Hematol; 2018 Jan; 97(1):51-61. PubMed ID: 28980058
[TBL] [Abstract][Full Text] [Related]
15. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
16. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
17. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
18. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.
Middeke JM; Herold S; Rücker-Braun E; Berdel WE; Stelljes M; Kaufmann M; Schäfer-Eckart K; Baldus CD; Stuhlmann R; Ho AD; Einsele H; Rösler W; Serve H; Hänel M; Sohlbach K; Klesse C; Mohr B; Heidenreich F; Stölzel F; Röllig C; Platzbecker U; Ehninger G; Bornhäuser M; Thiede C; Schetelig J;
Br J Haematol; 2016 Mar; 172(6):914-22. PubMed ID: 26771088
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
